News
The Augurex team brings together leading scientific, clinical, technical and commercial expertise to ensure that our research translates into advanced diagnostics for improved patient outcomes.
Augurex to participate in the SPARTAN 2025 Annual Meeting in Toronto, Canada
Augurex to participate in the SPARTAN 2025 Annual Meeting, taking place May 9–10 in Toronto, Canada. Featuring SPINEstat™, a Health Canada-approved, first-in-class blood test for the early diagnosis and monitoring of axial spondyloarthritis (axSpA). Vancouver, Canada...
Augurex to attend British Society for Rheumatology 2025 Annual Meeting in Manchester, UK
Augurex to attend British Society for Rheumatology 2025 Annual Meeting in Manchester, UK Highlighting biomarker-based diagnostic innovations for RA and axSpA Vancouver, Canada – April 25, 2025 – Augurex Life Sciences Corp., a leader in biomarker-based diagnostics for...
Augurex to attend CCR East 2025
Augurex to attend CCR East 2025 and present new research on 14-3-3eta auto-antibodies as a diagnostic marker for axial spondyloarthritis (axSpA). Augurex will be exhibiting at booth #66, showcasing how the 14-3-3eta test aids in the diagnosis and monitoring of...
Augurex Announces UKCA Authorization for SPINEstat™, Expanding Access of a First-in-Class Diagnostic Blood Test for Axial Spondyloarthritis to Great Britain
SPINEstat™, a novel, first-in-class diagnostic blood test for axial spondyloarthritis (axSpA), has received UKCA marking and is now listed as an IVD in the United Kingdom. This milestone expands access to an important new tool that addresses the long-standing...
Augurex Secures Health Canada Approval for SPINEstat™, a First-in-Class Diagnostic Blood Test for Axial Spondyloarthritis
SPINEstat™, a novel, first-in-class diagnostic blood test for axial spondyloarthritis (axSpA), has been approved by Health Canada. This approval marks an important milestone in addressing a significant global unmet need in axSpA. As an inflammatory autoimmune...
Augurex to Present New Data at Leading Rheumatology and Diagnostics Conferences in 2025
Vancouver, Canada – April 15, 2025 – Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced that multiple scientific abstracts have been accepted for presentation at major international rheumatology and diagnostics conferences...
Augurex featured in a RheumNow Therapeutic Update with Dr. Walter Maksymowych
Augurex is featured in a RheumNow Therapeutic Update with Dr. Walter Maksymowych, highlighting the role of 14-3-3eta across the RA care continuum. In this feature, Dr. Walter Maksymowych explores how 14-3-3eta helps close diagnostic and monitoring gaps in RA care....
Augurex Announces UK Conformity Assessed (UKCA) Authorization for JOINTstat®, Expanding Access to Cutting-Edge Rheumatoid Arthritis Testing in Great Britain
Augurex has received UK Conformity Assessed marking for JOINTstat®, authorizing its use in Great Britain for rheumatoid arthritis diagnosis and management. JOINTstat® is a well-established rheumatoid arthritis blood test in North America, approved by Health Canada and...
Augurex attends the TRS 2025 Annual Meeting
Vancouver, Canada – February 21, 2025 – Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced its participation in the Tennessee Rheumatology Society (TRS) 2025 Annual Meeting taking place from February 28 – March 1 in...
Augurex Announces UKCA Authorization for SPINEstat™, Expanding Access of a First-in-Class Diagnostic Blood Test for Axial Spondyloarthritis to Great Britain
SPINEstat™, a novel, first-in-class diagnostic blood test for axial spondyloarthritis (axSpA), has received UKCA marking and is now listed as an IVD in the United Kingdom. This milestone expands access to an important new tool that addresses the long-standing...
Augurex Secures Health Canada Approval for SPINEstat™, a First-in-Class Diagnostic Blood Test for Axial Spondyloarthritis
SPINEstat™, a novel, first-in-class diagnostic blood test for axial spondyloarthritis (axSpA), has been approved by Health Canada. This approval marks an important milestone in addressing a significant global unmet need in axSpA. As an inflammatory autoimmune...
Augurex featured in a RheumNow Therapeutic Update with Dr. Walter Maksymowych
Augurex is featured in a RheumNow Therapeutic Update with Dr. Walter Maksymowych, highlighting the role of 14-3-3eta across the RA care continuum. In this feature, Dr. Walter Maksymowych explores how 14-3-3eta helps close diagnostic and monitoring gaps in RA care....
Augurex Announces UK Conformity Assessed (UKCA) Authorization for JOINTstat®, Expanding Access to Cutting-Edge Rheumatoid Arthritis Testing in Great Britain
Augurex has received UK Conformity Assessed marking for JOINTstat®, authorizing its use in Great Britain for rheumatoid arthritis diagnosis and management. JOINTstat® is a well-established rheumatoid arthritis blood test in North America, approved by Health Canada and...
Biomarkers in Axial Spondyloarthritis: Dr. Walter Maksymowych on Spondycast
Vancouver, Canada – January 28, 2025 - The Spondylitis Association of America (SAA) invited Dr. Walter Maksymowych to join their latest episode of Spondycast, where he discusses the growing role of 14-3-3eta autoantibodies (Anti-14-3-3eta Multiplex) in the diagnosis...
Featured in SAA’s eSUN Newsletter: Advancing AxSpA Diagnosis with Anti-14-3-3eta Multiplex
Vancouver, Canada – January 27, 2025 – Delays in diagnosing axial spondyloarthritis (axSpA) have been a persistent challenge, with many patients waiting 7 to 10 years for an accurate diagnosis. These delays can lead to missed opportunities for early treatment and a...
Augurex Life Sciences and Quest Diagnostics Collaborate to Improve Rheumatoid Arthritis Diagnosis and Management
Quest to introduce lab-developed test based on Augurex 14-3-3η (eta) biomarker to U.S. physicians later this month Vancouver, Canada – November 15, 2024 – Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced that it...
Augurex and New Day Diagnostics Announce Launch of Anti-14-3-3eta Multiplex Analyte Specific Reagents; Enabling a First-In-Class Diagnostic Test for Axial Spondyloarthritis
Augurex launches Anti-14-3-3eta Multiplex Analyte Specific Reagents (ASRs), supporting the development of a first-in-class diagnostic test for axial spondyloarthritis (axSpA) by New Day Diagnostics. The new laboratory developed test, which uses Anti-14-3-3eta...
Augurex Announces Agreement with ARUP Laboratories to Expand Access to Advanced Rheumatoid Arthritis Diagnosis with the Launch of 14-3-3η (eta) Test
Augurex Life Sciences Corp. announces the launch of the 14-3-3η test by ARUP Laboratories, enhancing the early diagnosis and management of RA.The collaboration between Augurex and ARUP Laboratories highlights a mutual dedication to improving patient outcomes and...
Augurex to participate in the SPARTAN 2025 Annual Meeting in Toronto, Canada
Augurex to participate in the SPARTAN 2025 Annual Meeting, taking place May 9–10 in Toronto, Canada. Featuring SPINEstat™, a Health Canada-approved, first-in-class blood test for the early diagnosis and monitoring of axial spondyloarthritis (axSpA). Vancouver, Canada...
Augurex to attend British Society for Rheumatology 2025 Annual Meeting in Manchester, UK
Augurex to attend British Society for Rheumatology 2025 Annual Meeting in Manchester, UK Highlighting biomarker-based diagnostic innovations for RA and axSpA Vancouver, Canada – April 25, 2025 – Augurex Life Sciences Corp., a leader in biomarker-based diagnostics for...
Augurex to attend CCR East 2025
Augurex to attend CCR East 2025 and present new research on 14-3-3eta auto-antibodies as a diagnostic marker for axial spondyloarthritis (axSpA). Augurex will be exhibiting at booth #66, showcasing how the 14-3-3eta test aids in the diagnosis and monitoring of...
Augurex to Present New Data at Leading Rheumatology and Diagnostics Conferences in 2025
Vancouver, Canada – April 15, 2025 – Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced that multiple scientific abstracts have been accepted for presentation at major international rheumatology and diagnostics conferences...
Augurex attends the TRS 2025 Annual Meeting
Vancouver, Canada – February 21, 2025 – Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced its participation in the Tennessee Rheumatology Society (TRS) 2025 Annual Meeting taking place from February 28 – March 1 in...
Augurex attends the Canadian Rheumatology Association (CRA) 2025 Annual Scientific Meeting
Vancouver, Canada – February 19, 2025 – Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, is pleased to announce its participation in the Canadian Rheumatology Association (CRA) 2025 Annual Scientific Meeting, taking place February 26 –...
Augurex Attending RheumNow Live 2025
Vancouver, Canada – February 3, 2025 – Augurex is excited to announce that it will attend the RheumNow Live 2025 conference, a premier event bringing together leading rheumatologists and researchers to discuss the latest advancements in rheumatic disease diagnostics,...
Augurex to Present Axial Spondyloarthritis Data and Exhibit at ACR Convergence 2024 in Washington, DC
Augurex will present new research on 14-3-3η auto-antibodies as a diagnostic marker for axial spondyloarthritis. Augurex will be exhibiting at booth #2540, showcasing its innovative diagnostic for rheumatoid arthritis and newly launched first-in-class diagnostic test...
Augurex to Present Research on Novel Diagnostic 14-3-3η Auto-Antibody Marker for Axial Spondyloarthritis at the Spondylo Congress in Ghent
Vancouver, Canada – August 20, 2024 – Augurex Life Sciences Corp. today announced that it will be presenting a scientific poster at the upcoming Spondylo Congress, taking place in Ghent, Belgium, from September 5th to 7th, 2024. Augurex’s poster, titled "Novel...
Home
Products
Science
About
News
Careers
Contact